Limits...
Update on the optimal use of voriconazole for invasive fungal infections.

Lat A, Thompson GR - Infect Drug Resist (2011)

Bottom Line: It has a unique side effect profile compared with other azoles, as well as a number of clinically important drug-drug interactions.These factors, along with a correlation between increased serum levels and improved outcomes, have prompted an interest in therapeutic drug monitoring of this agent.The pharmacology and clinical outcomes data of voriconazole are presented in this review.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacy, New York-Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA;

ABSTRACT
Voriconazole is an extended-spectrum triazole with excellent bioavailability that has now become the treatment of choice for aspergillosis. It has a unique side effect profile compared with other azoles, as well as a number of clinically important drug-drug interactions. These factors, along with a correlation between increased serum levels and improved outcomes, have prompted an interest in therapeutic drug monitoring of this agent. The pharmacology and clinical outcomes data of voriconazole are presented in this review.

No MeSH data available.


Related in: MedlinePlus

Targets of systemic antifungal agents.Reproduced with permission from reference 6.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3108750&req=5

f1-idr-4-043: Targets of systemic antifungal agents.Reproduced with permission from reference 6.

Mentions: The azoles enact their antifungal effects within the fungal cell membrane by blocking the P450 (CYP)-dependent demethylation of lanosterol, leading to the inhibition of ergosterol synthesis (Figure 1). This process causes toxic methylsterols to accumulate in the fungal cell membrane and prevents fungal cell growth and replication. Differences between azoles in antifungal potency and activity are attributed to differences in their affinity for the 14-α-demethylase enzyme. The toxicity and drug interaction profiles of the azoles, including voriconazole, are due to cross-inhibition of various human CYP-dependent enzymes. Voriconazole, like other triazoles, is fungistatic against most yeasts but has fungicidal activity against molds, including Aspergillus.8–10


Update on the optimal use of voriconazole for invasive fungal infections.

Lat A, Thompson GR - Infect Drug Resist (2011)

Targets of systemic antifungal agents.Reproduced with permission from reference 6.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3108750&req=5

f1-idr-4-043: Targets of systemic antifungal agents.Reproduced with permission from reference 6.
Mentions: The azoles enact their antifungal effects within the fungal cell membrane by blocking the P450 (CYP)-dependent demethylation of lanosterol, leading to the inhibition of ergosterol synthesis (Figure 1). This process causes toxic methylsterols to accumulate in the fungal cell membrane and prevents fungal cell growth and replication. Differences between azoles in antifungal potency and activity are attributed to differences in their affinity for the 14-α-demethylase enzyme. The toxicity and drug interaction profiles of the azoles, including voriconazole, are due to cross-inhibition of various human CYP-dependent enzymes. Voriconazole, like other triazoles, is fungistatic against most yeasts but has fungicidal activity against molds, including Aspergillus.8–10

Bottom Line: It has a unique side effect profile compared with other azoles, as well as a number of clinically important drug-drug interactions.These factors, along with a correlation between increased serum levels and improved outcomes, have prompted an interest in therapeutic drug monitoring of this agent.The pharmacology and clinical outcomes data of voriconazole are presented in this review.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacy, New York-Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA;

ABSTRACT
Voriconazole is an extended-spectrum triazole with excellent bioavailability that has now become the treatment of choice for aspergillosis. It has a unique side effect profile compared with other azoles, as well as a number of clinically important drug-drug interactions. These factors, along with a correlation between increased serum levels and improved outcomes, have prompted an interest in therapeutic drug monitoring of this agent. The pharmacology and clinical outcomes data of voriconazole are presented in this review.

No MeSH data available.


Related in: MedlinePlus